Surface CALR Chemical Inducers for HSC Quality Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The signals triggering calreticulin (CALR) expression on hematopoietic stem cell (HSC) surfaces, which mediate their removal or amplification, remain unknown, impacting the quality assurance and proliferation of HSCs.
Innovation Solution
Identification of CALR agonists that modulate CALR expression on HSC surfaces through ROS induction or independently, promoting either full engulfment by macrophages for quality assurance or partial engulfment for proliferation, using a panel of 1200 bioactive small molecules screened for robust dosage responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CALR agonists are administered to promote HSC proliferation, then healthy HSC survival is improved, but pathological hematopoiesis may be enhanced
Solution Approach 1:
The patent applies local quality by differentiating the effect of CALR agonists on different HSC populations. The agonists selectively promote proliferation of healthy HSCs while having differential effects on pathological HSCs, allowing targeted therapeutic action. This is achieved through the specific biochemical properties of the identified compounds that respond to cellular stress states and macrophage interaction signals.
Solution Approach 2:
The patent inverts the traditional approach by using macrophage-HSC interaction signals (CALR expression) as a therapeutic target rather than treating it as a side effect. By administering CALR agonists to enhance this interaction, the therapy promotes quality assurance mechanisms that naturally eliminate damaged cells while preserving healthy ones, turning a previously unexplored mechanism into a therapeutic advantage.
2Reliability
If macrophage-HSC interactions are enhanced through CALR upregulation, then HSC quality assurance is improved, but HSC proliferation may be reduced
Solution Approach 1:
The patent applies partial action by inducing moderate CALR upregulation that is sufficient to enhance macrophage-HSC interactions and quality assurance, but not so excessive as to completely suppress proliferation. The identified agonists achieve an optimal balance where partial engulfment signals promote survival without triggering complete elimination of the HSC population.
Solution Approach 2:
The patent changes the parameter of CALR surface expression levels through pharmacological intervention. By precisely controlling the degree of CALR upregulation via specific agonist concentrations and formulations, the therapy optimizes the balance between quality assurance (requiring higher CALR) and proliferation (requiring moderate CALR levels).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified CALR agonists effectively regulate HSC interactions with macrophages, reducing pathological hematopoiesis and enhancing healthy HSC proliferation and survival, offering therapeutic potential for conditions like clonal hematopoiesis, myelodysplastic syndrome, and leukemia.
Implementation Method 1
ROS+ drugs were associated with FOXO1A and oxidative stress
Data Source
AI summary
ROS signal upregulates surface CALR and promotes macrophage-HSC interactions, safeguarding the development of stem cells that are stressed or damaged. Described herein are methods of controlling hematopoiesis, e.g., reducing hematopoiesis and/or improving the quality control mechanisms of hematopoiesis, relating to the use or administration of at least one CALR agonist.